BAUSCH + LOMB CORP
NYSE: BLCO (Bausch + Lomb Corporation)
Last update: 11 hours ago15.07
0.51 (3.50%)
| Previous Close | 14.56 |
| Open | 14.57 |
| Volume | 403,232 |
| Avg. Volume (3M) | 516,740 |
| Market Cap | 5,337,639,936 |
| Price / Earnings (Forward) | 14.45 |
| Price / Sales | 1.04 |
| Price / Book | 0.810 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Bausch + Lomb Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.10 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Icahn Carl C | 30 Sep 2025 | 3,500,000 |
| Silver Point Capital L.P. | 30 Sep 2025 | 2,565,000 |
| Glenview Capital Management, Llc | 30 Sep 2025 | 1,553,855 |
| Diameter Capital Partners Lp | 30 Sep 2025 | 1,215,893 |
| Compass Rose Asset Management, Lp | 30 Sep 2025 | 1,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (RBC Capital, 26.08%) | Buy |
| 19.00 (Raymond James, 26.08%) | Buy | |
| Median | 17.00 (12.81%) | |
| Low | 16.00 (JP Morgan, 6.17%) | Hold |
| 16.00 (Goldman Sachs, 6.17%) | Hold | |
| Average | 17.38 (15.33%) | |
| Total | 4 Buy, 4 Hold | |
| Avg. Price @ Call | 15.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 14 Nov 2025 | 19.00 (26.08%) | Buy | 15.60 |
| Wells Fargo | 14 Nov 2025 | 17.00 (12.81%) | Hold | 15.60 |
| 30 Oct 2025 | 16.00 (6.17%) | Hold | 15.14 | |
| Barclays | 31 Oct 2025 | 17.00 (12.81%) | Hold | 14.94 |
| HC Wainwright & Co. | 31 Oct 2025 | 17.00 (12.81%) | Buy | 14.94 |
| Evercore ISI Group | 30 Oct 2025 | 18.00 (19.44%) | Buy | 15.14 |
| 07 Oct 2025 | 17.00 (12.81%) | Buy | 14.66 | |
| JP Morgan | 30 Oct 2025 | 16.00 (6.17%) | Hold | 15.14 |
| Raymond James | 30 Oct 2025 | 19.00 (26.08%) | Buy | 15.14 |
| Goldman Sachs | 01 Oct 2025 | 16.00 (6.17%) | Hold | 14.67 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PAULSON JOHN | 15.60 | - | 1,402 | 21,871 |
| ROBERTSON RUSSEL C | 15.60 | - | 1,642 | 25,615 |
| Aggregate Net Quantity | 3,044 | |||
| Aggregate Net Value ($) | 47,486 | |||
| Aggregate Avg. Buy ($) | 15.60 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PAULSON JOHN | Director | 14 Nov 2025 | Acquired (+) | 1,402 | 15.60 | 21,871 |
| ROBERTSON RUSSEL C | Director | 14 Nov 2025 | Acquired (+) | 1,642 | 15.60 | 25,615 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |